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with non-psychiatric indications (12 out of 13284). Risk of idea-
tion or worse was reduced in participants with any psychiatric 
indication, but this was of borderline signifi cance (OR 0.83, 95% 
CI 0.69 to 1.00; p=0.05). Suicide behavioural risk (completed sui-
cide, attempted suicide or preparatory acts) was associated with 
age; participants aged <25 years had increased risk of suicidal 
behaviour with active treatment versus placebo, OR 2.30, 95% 
CI 1.04 to 5.09. Treatment was associated with a reduced risk 
of suicidal behaviour in the age group of 25 to 64 years, but this 
was not signifi cant (OR 0.87, 95% CI 0.58 to 1.29). Participants 
aged ≥65 years showed a reduced risk of suicidal behaviour with 
active drug treatment (OR 0.06, 95% CI 0.01 to 0.58). When sui-
cidal behaviour was grouped with ideation the age <25 years 
group showed a non-signifi cant trend towards increased risk with 
active treatments (OR 1.62, 95% CI 0.97 to 2.71), whereas both 
the 25 to 64 years age group and the group of persons aged ≥65 
years showed a reduced risk (OR 0.79, 95% CI 0.64 to 0.98; OR 
0.37, 95% CI 0.18 to 0.76 respectively). When age was modelled 
as a continuous variable, the OR for suicidal behaviour or idea-
tion declined at a rate of 2.6% per year of age (−3.9% to −1.3% 
p=0.0001) and the OR for suicidal behaviour declined at a rate of 
4.6% per year of age (−7.4 % to −1.8% p=0.001).
CONCLUSIONS
The evidence suggests that there is an increased risk of suicidal 
behaviour in adults aged <25 years who receive antidepres-
sants. Those aged ≥25 years have no increased or decreased 
risk (in people aged 65 years or older).
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QUESTION
Question: What is the risk of suicidal behaviour within clini-
cal trials of antidepressants in adults?
Outcomes: Primary outcome: defi nitive suicidal behaviour or 
 ideation (completed suicide, attempted suicide or  preparatory acts), 
secondary outcome: suicidal behaviour (preparatory actions).
METHODS
Design: Systematic review with meta-analysis.
Data sources: Data requested from 8 industry sponsors of 12 
marketed antidepressant products were used. FDA-specifi ed 
data formats provided instructions for identifying and clas-
sifying events possibly related to suicidality and how events 
would be classifi ed. The search date was not reported, and the 
majority of trials were unpublished.
Study selection and analysis: Double-blind randomised 
placebo-controlled trials assessed the use of one of the 12 
antidepressants in adults for any indication of suicidality. 
The antidepressants were bupropion, citalopram, duloxetine, 
escitalopram, fl uoxetine, fl uoxetine/olanzapine (ultimately 
excluded from the analysis), fl uvoxamine, mirtazapine, nefa-
zodone, paroxetine, sertraline and venlafaxine. A total of 372 
trials (n=99 231) were included in the dataset. Trials limited to 
known drug responders, those with fewer than 20 participants, 
studies not providing patient level data and studies with non-
antidepressant active control were excluded. Individual patient-
level data were analysed using a conditional logistic regression 
model. Heterogeneity between studies was assessed.
MAIN RESULTS
There were a total of 8 (0.01%) completed suicides, 134 (0.14%) 
attempted suicides and 378 (0.38%) people experiencing ideation 
alone. Overall, there was no increased risk of suicidality (ideation 
or worse) with active treatment versus placebo (OR 0.85, 95% CI 
0.71 to 1.02; p=0.08). Ideation or worse was rare in participants 
It has been known for a long time that anti-depressants can increase the risk of suicidal thoughts and behaviour.1 Stone and colleagues 
have conducted a re-analyses of FDA data of 372 
randomised placebo-controlled efficacy trials con-
ducted not only in the indication of major depressive 
disorder but also in all other psychiatric and non-
psychiatric indications. Main results indicated that 
the risk for suicidal behaviour in patients aged <25 
years taking antidepressants as compared to pla-
cebo was significantly elevated, neutral in patients 
aged 25 to 64 years and protective for those aged 
≥65 years. The second result was the strong age-
relatedness of suicidal behaviour. On the basis of 
these two main results, the FDA ordered that for 
all antidepressants the existing black-box warning 
should be updated to include warnings about sui-
cidality of young adults. However, such warnings 
may discourage psychiatrists from using antide-
pressants, which in turn might increase suicidality. 
Gibbons2 showed that after the release of the FDA 
warnings the antidepressant prescription rates 
decreased in the USA and the Netherlands, by 
about 22%. Simultaneously, the suicide rates in 
youths increased up to 49% in the Netherlands and 
up to 14% in the USA.
This raises the question whether these fi ndings 
really justify such a drastic step. There is, beyond 
doubt, a strong age-relatedness, but the increased 
risk for suicidal behaviour in young adults aged <25 
years alone is only just statistically signifi cant. The 
second main fi nding, of the age-relatedness of sui-
cidal behaviour, is strongly dependent on the robust 
suicide protective effect in higher ages, which per se 
also does not necessarily suggest a suicide warning 
that has general effects on overall antidepressant pre-
scription rates.
The discovery of age as an infl uential variable of 
antidepressant-induced suicidal behaviour signifi -
cantly adds to our knowledge, opens new research 
fi elds and suggests closer suicidality monitoring in 
clinical daily routine. However, though the paper 
by Stone and colleagues is a landmark in suicide 
research, the consequential FDA black-box warnings 
may not have been fully justifi ed.
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